If membranous IR overexpression could be used as a predictive biomarker to opt for or against a tyrosine kinase inhibitor therapy, this would be particularly useful for therapeutic decision-making in the vulnerable subgroup of patients with advanced HCC and Child-Pugh stage B. The IR expression status has the potential to refine therapeutic decision-making in HCC therapy and should therefore be further investigated. This evidence concerns the gene INSR and hepatocellular carcinoma.